« Return to News | R&D Trends

China-based WuXi Reports Successful Second Quarter

Tuesday, August 19, 2008 11:18 AM

A year after going public on the New York Stock Exchange, Chinese contract research, development and manufacturing company WuXi PharmaTech reported second quarter net revenues of $70.8 million—a 134% increase compared with the same period last year.

Established in 2000, WuXi has enjoyed several successes the past year. The company acquired a U.S.-based laboratory services supplier in January, and in late June, WuXi and contract research organization (CRO) Covance announced plans to form a partnership to provide preclinical contract research services in China, a move that will enable WuXi to access Covance’s deep customer base. WuXi's current big pharma clients include Merck and AstraZeneca. In addition to its operations in China, WuXi runs R&D and manufacturing facilities in St. Paul, Minn.; Atlanta, Ga; and Philadelphia, Pa.

According to WuXi’s second quarter earnings report, net revenues from laboratory services increased to $45.2 million, up 80% from Q2 2007, and manufacturing services net revenues grew almost 400% to $25.6 million. The January acquisition of AppTec was supposed to have contributed to WuXi’s impressive revenue growth, but WuXi did not provide specific financial details about this acquisition.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.